Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Clinical Update

COX-2 inhibitors and renal function in elderly people

Benjamin H. Chen
CMAJ September 05, 2000 163 (5) 604;
Benjamin H. Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: a randomized, controlled trial. Ann Intern Med 2000; 133:1-9.

Background

About 10 million prescriptions for NSAIDs are dispensed yearly in Canada.1 NSAIDs exert their effects through the inhibition of cyclo-oxygenase (COX), an enzyme that catalyses the synthesis of prostaglandins. Two isoforms of COX (COX-1 and COX-2) have been identified. Traditional NSAIDs inhibit both of them, whereas the newer COX-2 inhibitors selectively inhibit COX-2. Although renal failure can occur with traditional NSAIDs, it is unclear whether this risk can be avoided with the use of COX-2 inhibitors.

Question

Does rofecoxib, a COX-2 inhibitor, impair renal function in elderly people?

Design

This randomized, double-blind, placebo-controlled trial enrolled elderly people aged 65‐80 years.2 Numerous exclusion criteria applied; all subjects were in good general health and took no medications that might impair renal function. Subjects were randomly assigned to receive a 5-day course of one of the following treatments: rofecoxib, 12.5 mg/d; rofecoxib, 25 mg/d; indomethacin, 50 mg 3 times daily; or placebo. All subjects were placed on a low-sodium diet 8 days before randomization. The primary end point was the glomerular filtration rate (GFR), calculated by measuring iodine-125‐ iothalamate clearance before and after treatment.

Results

Sixty subjects (15 in each treatment arm) completed the study. The mean age was 72 years. Compared with placebo, multiple doses of rofecoxib 12.5 mg/d, rofecoxib 25 mg/d and indomethacin 150 mg/d decreased the GFR by a mean of 0.14 mL/s (p = 0.019), 0.13 mL/s (p = 0.029) and 0.10 mL/s (p = 0.086) respectively. The reductions in GFR were comparable between the rofecoxib and indomethacin groups.

Commentary

This study found that rofecoxib impaired renal function among the elderly subjects as much as a traditional NSAID. The results are likely generalizable to other COX-2 inhibitors, given similar findings with celecoxib.3 Whether the results can be generalized to younger patients is unknown. The low-sodium diet, which mimics a state of decreased circulating volume, may have exaggerated the observed reduction in GFR. Conversely, the exclusive use of healthy subjects and the short duration of drug exposure may have underestimated the usual risk among elderly patients. Of note, this study did not look for other renal complications of NSAIDs, such as interstitial nephritis.

Practice implications

Like traditional NSAIDs, selective COX-2 inhibitors can impair renal function. These drugs, therefore, should be used with caution in elderly patients, in patients with renal insufficiency and in patients with decreased circulating volume because of diuretic use, congestive heart failure or cirrhosis. —

The Clinical Update section is edited by Dr. Donald Farquhar, head of the Division of Internal Medicine, Queen‚s University, Kingston, Ont. The updates are written by members of the division.

References

  1. 1.↵
    Tamblyn R, Berkson L, Dauphinee D, Gayton D, Grad R, Huang A, et al. Unnecessary prescribing of NSAIDs and the management of NSAID-related gastropathy in medical practice. Ann Intern Med 1997;127:429-38.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Swan SK, Rudy DW, Lasseter KC, Ryan CF, Buechel KL, Lambrecht LJ, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: a randomized, controlled trial. Ann Intern Med 2000; 133:1-9.
    OpenUrlPubMed
  3. 3.↵
    Rossat J, Maillard M, Nussberger J, Brunner HR, Burnier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999;66: 76-84.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

CMAJ
Vol. 163, Issue 5
5 Sep 2000
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
COX-2 inhibitors and renal function in elderly people
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
COX-2 inhibitors and renal function in elderly people
Benjamin H. Chen
CMAJ Sep 2000, 163 (5) 604;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
COX-2 inhibitors and renal function in elderly people
Benjamin H. Chen
CMAJ Sep 2000, 163 (5) 604;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Update on Cyclooxygenase-2 Inhibitors
  • The double-edged sword of COX-2 selective NSAIDs
  • Google Scholar

More in this TOC Section

  • Early treatment of acute hepatitis C infection may lead to cure
  • Angiotensin-II–receptor blockers and nephropathy in patients with type 2 diabetes
  • Colorectal cancer screening: you can't be positive about a negative result
Show more Clinical Update

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire